Israel - English - Ministry of Health

takeda israel ltd - idursulfase - concentrate for solution for infusion - idursulfase 2 mg/ml - idursulfase - idursulfase - long term treatment of patients with hunter syndrome (mps ii).

European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - idursulfase - mucopolysaccharidosis ii - other alimentary tract and metabolism products, - elaprase is indicated for the long-term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii). heterozygous females were not studied in the clinical trials.

Singapore - English - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - idursulfase - infusion, solution concentrate - 6.0 mg/vial - idursulfase 6.0 mg/vial

Canada - English - Health Canada

takeda canada inc - idursulfase - solution - 2mg - idursulfase 2mg - enzymes

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

shire human genetic therapies ab, sweden - idursulfase - concentrate for solution for infusion - 2 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

shire human genetic therapies ab, sweden - idursulfase - concentrate for solution for infusion - 2 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - idursulfase 2 mg/ml;   - concentrate for infusion - 2 mg/ml - active: idursulfase 2 mg/ml   excipient: dibasic sodium phosphate heptahydrate monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride water for injection - elaprase is indicated for the long term treatment of patients with hunter syndrome (mucopolysaccharidosis ii, mps ii).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

shire pharmaceuticals ltd - idursulfase - solution for infusion - 2mg/1ml